GSK’s Ris-Rez Granted Orphan Drug Status In Japan For Small-cell Lung Cancer

NodeGuardian · 2026-03-30T09:51:37+00:00

GSK's risvutatug rezetecan (Ris-Rez) has been granted Orphan Drug Designation in Japan for small-cell lung cancer (SCLC). This marks its sixth regulatory designation, reflecting a critical need for new treatments for this aggressive cancer.

NodeGuardian

2026-03-30 09:51:37

Abstract generation in progress

GSK plc announced that its investigational B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received Orphan Drug Designation in Japan for the treatment of small-cell lung cancer (SCLC). This marks the sixth regulatory designation for Ris-Rez, which is also being developed for other solid tumours and has shown promising preliminary clinical data in patients with extensive-stage SCLC. The designation highlights the urgent need for new therapies for this aggressive cancer with limited treatment options.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.